LncRNA-DGCR5在非小细胞肺癌中的表达及与放疗疗效、预后的相关性分析  

Expression of LncRNA-DGCR5 in non-small cell lung cancer and itscorrelation with radiotherapy efficacy and prognosis

作　　者：韩康 景文江 伍永升 李源 范志刚 HAN Kang;JING Wenjiang;WU Yongsheng;LI Yuan;FAN Zhigang(Department of Respiratory and Critical Care Medicine,3201 Hospital,Hanzhong,Shaanxi 723000,China;不详)

机构地区：[1]三二〇一医院呼吸与危重症医学科,陕西汉中723000 [2]三二〇一医院放疗科 [3]三二〇一医院肿瘤内一科

出　　处：《中华全科医学》2025年第2期203-206,共4页Chinese Journal of General Practice

基　　金：陕西省重点研发计划项目(2021SF-044)。

摘　　要：目的 探讨LncRNA-DGCR5在非小细胞肺癌(NSCLC)中的表达及临床意义。方法 收集2020年1月—2021年1月三二〇一医院收治的105例NSCLC患者,根据LncRNA-DGCR5表达情况分为低表达组(41例)和高表达组(64例),分析LncRNA-DGCR5表达量与患者放疗疗效、预后的关系。结果 癌组织LncRNA-DGCR5表达水平低于癌旁组织(1.21±0.45 vs. 4.02±0.89,t=28.872,P<0.05)。低表达组相比于与高表达组肿瘤低分化占比、TNM分期为Ⅲ~Ⅳ期占比更高(63.41%vs. 17.19%,χ^(2)=23.401,P<0.05;56.10%vs. 32.81%,χ^(2)=5.566,P<0.05),客观缓解率更低(46.34%vs. 87.50%,χ^(2)=27.648,P<0.05),3年无病生存时间(DFS)更短(27.00个月vs. 31.00个月,log-rankχ^(2)=10.120,P<0.05)。肿瘤低分化、TNM分期为Ⅲ~Ⅳ期、存在淋巴结转移患者中位DFS更低,分别为28.15、28.66、27.45个月(χ^(2)=9.074、5.105、12.116,均P<0.05)。肿瘤分化程度、TNM分期、淋巴结转移及LncRNA-DGCR5表达均为影响NSCLC患者中位DFS的相关因素(P<0.05)。结论 LncRNA-DGCR5在NSCLC癌组织中呈低表达,与患者放疗疗效及预后密切相关。Objective To investigate the expression and clinical significance of LncRNA-DGCR5 in non-small cell lung cancer(NSCLC).Methods A total of 105 NSCLC patients admitted to 3201 Hospital from January 2020 to January 2021 were collected.The expression levels of LncRNA-DGCR5 were detected,and the patients were divided into a low expression group(n=41)and a high expression group(n=64).The relationship between the expression level of LncRNA-DGCR5,the radiotherapy efficacy,and prognosis of patients was analyzed.Results The expression level of LncRNA-DGCR5 in cancer tissues was significantly lower than that in adjacent tissues(1.21±0.45 vs.4.02±0.89,t=28.872,P<0.05).Compared with the high expression group,the proportion of poorly differentiated tumor and TNM stageⅢtoⅣin the low expression group was higher(63.41%vs.17.19%,56.10%vs.32.81%,χ^(2)=23.401,5.566,P<0.05).In contrast to the high expression group,the objective response rate was lower(46.34%vs.87.50%,χ^(2)=27.648,P<0.05),and the 3-year disease-free survival(DFS)was shorter(27.00 months vs.31.00 months,log-rankχ^(2)=10.120,P<0.05)in the low expression group.Additionally,patients with low tumor differentiation,TNM stageⅢtoⅣ,and lymph node metastasis had lower median DFS(28.15,28.66,27.45 months,respectively,χ^(2)=9.074,5.105,12.116,all P<0.05).Tumor differentiation,TNM stage,lymph node metastasis,and LncRNA-DGCR5 expression were all significantly associated with median DFS in NSCLC patients(P<0.05).Conclusion LncRNA-DGCR5 is expressed at low levels in NSCLC tissues and is closely related to the radiotherapy efficacy and patient prognosis.

关 键 词：LncRNA-DGCR5 非小细胞肺癌 放疗疗效 预后 

分 类 号：R734.2[医药卫生—肿瘤] R730.55[医药卫生—临床医学]